Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

Ji, Sang-Won; Kim, Hyun Soo; Kim, Jae Woo; Jee, M. K. Dewan; Park, Kwang Wha; Uh, Young; Lee, Dong Ki; Song, Jae Seok; Baik, Soon Koo; Kwon, Sang Ok

doi:10.1111/j.1440-1746.2006.04314.x

Cited by 17 publications

(16 citation statements)

References 37 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The typical rabeprazole dose is 20 mg; however, previous reports showed that 10 mg of rabeprazole was equivalent to 20 mg of omeprazole in gastric ulcer healing after 6 weeks [16]. The goal of our study was to compare the efficacy of 10 mg rabeprazole to 20 mg rabaprazole in patients with ESD-induced ulcers.…”

Section: Discussionmentioning

confidence: 95%

“…Among the many available PPIs, rabeprazole is commonly used in Asian countries because it is less affected by the CYP2C19 genetic polymorphism, which is more prevalent in Japan, China, and Korea than in western countries [15,16,24]. The typical rabeprazole dose is 20 mg; however, previous reports showed that 10 mg of rabeprazole was equivalent to 20 mg of omeprazole in gastric ulcer healing after 6 weeks [16].…”

Section: Discussionmentioning

confidence: 97%

“…The usual dose of rabeprazole is 20 mg; however, a previous report suggested that a 10-mg dose of rabeprazole had effects equivalent to 20 mg of omeprazole for the purpose of gastric ulcer healing [16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Half-Dose Rabeprazole Has an Equal Efficacy to Standard-Dose Rabeprazole on Endoscopic Submucosal Dissection-Induced Ulcer

Park

Kim

et al. 2012

Dig Dis Sci

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Half-Dose Rabeprazole Has an Equal Efficacy to Standard-Dose Rabeprazole on Endoscopic Submucosal Dissection-Induced Ulcer

Park

Kim

et al. 2012

Dig Dis Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fort he managementof PU (induction of healing and maintenanceo fremission) bothsuppression of gastric acid secretion and eradication of Hpareimportantmainstays.Ing eneral,therei slittle overall differencei nPU healing ratesamong the PPIsand reported small differencescanbeexplained best bythe variable dosage regimensapplied [57,89,159].Eradication of Hpi saccomplished efficiently(80-90%e radication rates)by standardtriple therapywithaPPI, amoxicillin and clarithromycin ormetronidazole [17,29,91]and therewasno significantdifferenceamong the PPIs [35,36,76,141,151].…”

Section: Therapeuticuseo Fppis 51 Pepticulcermentioning

confidence: 99%

Proton Pump Inhibitors – Their Pharmacological Impact on the Clinical Management of Acid-Related Disorders

Klotz

2011

Arzneimittelforschung

View full text Add to dashboard Cite

Acid secretion or intragastric pH play a very important role in the pathophysiology of acid-related disorders such as peptic ulcer (PU), gastrooesophageal reflux disease (GERD) or nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal lesions. Proton pump inhibitors (PPIs) represent the most potent/effective antisecretory drugs for these indications. For the selection among the various agents (omeprazole/esomeprazole (CAS 73590-58-6/119141-88-7), pantoprazole (CAS 102625-70-7), lansoprazole (CAS103577-45-3), rabeprazole (CAS 117976-83-3)) some features of their pharmacokinetic (PK) and pharmacodynamic (PD) properties should be considered as the clinical outcome depends on systemic drug exposure (PK) and elevation of intragastric pH about certain threshold levels (PD). The present review updates PK, PD and clinical data to provide some guidance between the PPIs which differ somewhat in their metabolic pattern and drug interaction potential. Based on 24-h intragastric pH assessments the relative potencies of the PPIs compared to omeprazole were in healthy volunteers (in GERD patients): 0.42 (0.59), 1.0 (0.8), 1.0 (1.0), 1.25 (1.25) and 2.0 (1.4) for pantoprazole, lansoprazole, omeprazole, esomeprazole and rabeprazole, respectively. In general, the clinical benefits of PPI are well documented but some patients can be regarded as non-responders and thus represent a challenge for future clinical research.

show abstract

“…It should be noted that in contrast to H. pylori eradication, there is little overall difference in peptic ulcer healing rates among the PPIs in the management of PUD [195], and it is possible that pharmacogenomics may not explain interindividual differences enough to the extent that different dose regimens can be applied [4,197,198]. On a broader scale, a call for a pharmacogenetic-based dose alteration needs to be tempered with the global status of pharmacogenetic individualization of therapy, which remains in evolution and currently has limited application in medical practice [199].…”

Section: Expert Commentarymentioning

confidence: 99%

Acid peptic diseases: pharmacological approach to treatment

Mejia

Kraft

2009

Expert Review of Clinical Pharmacology

105

View full text Add to dashboard Cite

Acid peptic disorders are the result of distinctive, but overlapping pathogenic mechanisms leading to either excessive acid secretion or diminished mucosal defense. They are common entities present in daily clinical practice that, owing to their chronicity, represent a significant cost to healthcare. Key elements in the success of controlling these entities have been the development of potent and safe drugs based on physiological targets. The histamine-2 receptor antagonists revolutionized the treatment of acid peptic disorders owing to their safety and efficacy profile. The proton-pump inhibitors (PPIs) represent a further therapeutic advance due to more potent inhibition of acid secretion. Ample data from clinical trials and observational experience have confirmed the utility of these agents in the treatment of acid peptic diseases, with differential efficacy and safety characteristics between and within drug classes. Paradigms in their speed and duration of action have underscored the need for new chemical entities that, from a single dose, would provide reliable duration of acid control, particularly at night. Moreover, PPIs reduce, but do not eliminate, the risk of ulcers in patients taking NSAIDs, reflecting untargeted physiopathologic pathways and a breach in the ability to sustain an intragastric pH of more than 4. This review provides an assessment of the current understanding of the physiology of acid production, a discussion of medications targeting gastric acid production and a review of efficacy in specific acid peptic diseases, as well as current challenges and future directions in the treatment of acid-mediated diseases.

show abstract

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

Abstract: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.

Cited by 17 publications

References 37 publications

Half-Dose Rabeprazole Has an Equal Efficacy to Standard-Dose Rabeprazole on Endoscopic Submucosal Dissection-Induced Ulcer

Half-Dose Rabeprazole Has an Equal Efficacy to Standard-Dose Rabeprazole on Endoscopic Submucosal Dissection-Induced Ulcer

Proton Pump Inhibitors – Their Pharmacological Impact on the Clinical Management of Acid-Related Disorders

Acid peptic diseases: pharmacological approach to treatment

Contact Info

Product

Resources

About